- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02755324
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leiden, Netherlands, 2333 ZA
- Leiden University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is aged ≥ 18 and ≤ 45 years and in good health.
- Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
- Subject is able to communicate well with the investigator, is available to attend all study visits.
- Subject will remain within Europe (excluding Corsica) during the study period and is reachable by mobile telephone from week 3 to week 12 of the study period.
- Subject agrees to refrain from blood donation throughout the study period.
- For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
- Subject has signed informed consent.
Exclusion Criteria:
Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
- body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;
- positive HIV, hepatitis B or hepatitis C screening tests;
- the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period;
- history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
- any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
- history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
- Any clinically significant abnormalities (including extended QT interval) on electrocardiogram
- The chronic use of any drug known to interact with praziquantel, or artesunate or lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine, amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics, antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval are excluded from the study.
- For female subjects: positive urine pregnancy test at screening.
- Any history of schistosomiasis or treatment for schistosomiasis.
- Positive serology for schistosomiasis or elevated serum or urine circulating anodic antigen or positive Schistosoma serology at baseline.
- Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel or, artesunate or lumefantrine.
- Being an employee or student of the department of parasitology or infectious diseases of the Leiden University Medical Center.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
|
Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae.
Time Frame: 20 weeks
|
20 weeks
|
The number of male cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen (CAA).
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average number of weeks until positive serum circulating anodic antigen test
Time Frame: 12 weeks
|
12 weeks
|
Comparison of the height of the peak serum circulating anodic antigen concentration in low dose compared with high dose group
Time Frame: 12 weeks
|
12 weeks
|
Comparison of the humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals
Time Frame: 1 year
|
1 year
|
Differences in in ex vivo lymphocyte profiles between infected and uninfected individuals
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Meta Roestenberg, LUMC
Publications and helpful links
General Publications
- Langenberg MCC, Hoogerwerf MA, Janse JJ, van Lieshout L, Corstjens PLAM, Roestenberg M; CoHSI clinical trial team. Katayama Syndrome Without Schistosoma mansoni Eggs. Ann Intern Med. 2019 May 21;170(10):732-733. doi: 10.7326/L18-0438. Epub 2019 Jan 8. No abstract available.
- Langenberg MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, Kos-van Oosterhoud J, Feijt C, Jochems SP, de Dood CJ, van Schuijlenburg R, Ozir-Fazalalikhan A, Manurung MD, Sartono E, van der Beek MT, Winkel BMF, Verbeek-Menken PH, Stam KA, van Leeuwen FWB, Meij P, van Diepen A, van Lieshout L, van Dam GJ, Corstjens PLAM, Hokke CH, Yazdanbakhsh M, Visser LG, Roestenberg M. A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics. Nat Med. 2020 Mar;26(3):326-332. doi: 10.1038/s41591-020-0759-x. Epub 2020 Feb 17.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CoHSI1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schistosomiasis
-
Oswaldo Cruz FoundationRecruitingVaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis HaematobiumSenegal
-
Rhode Island HospitalLondon School of Hygiene and Tropical Medicine; Medical Research Council; University... and other collaboratorsRecruitingSchistosomiasis | Schistosomiasis Mansoni | Schistosoma Japonicum InfectionUganda, United Kingdom
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosomiasis MansoniNetherlands
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Oswaldo Cruz FoundationUniversidade Federal de Pernambuco; World Health OrganizationCompletedSchistosomiasis Mansoni
-
Enaiblers ABMinistry of Health, Uganda; Jimma University; Ghent University, BelgiumNot yet recruitingSchistosomiasis Mansoni | Soil Transmitted Helminths
-
IRCCS Sacro Cuore Don Calabria di NegrarActive, not recruiting
-
Makerere UniversityUniversity of CopenhagenCompleted
-
Makerere UniversityUniversity of CopenhagenUnknown
Clinical Trials on male Schistosoma mansoni cercariae
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosomiasis MansoniNetherlands
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosoma MansoniNetherlands
-
Leiden University Medical CenterMRC/UVRI and LSHTM Uganda Research Unit; Texas Tech University Health Sciences...Not yet recruitingSchistosomiasis | Schistosoma Mansoni
-
Hospital Universitário Professor Edgard SantosOswaldo Cruz Foundation; Conselho Nacional de Desenvolvimento Científico e...CompletedCutaneous Leishmaniasis, AmericanBrazil
-
CM Chungmu HospitalKorea United Pharm. Inc.UnknownNausea | VomitingKorea, Republic of